[HIV-STD-Prevention] Weekly Prevention Resources - 12/11/24 #u#

Wed Dec 11 14:14:15 PST 2024

Hello, HIV and STI Prevention partners!

Welcome to this week’s HIV/STI Prevention listserv email! Please email me at shelley.m.pearson at oha.oregon.gov<mailto:shelley.m.pearson at oha.oregon.gov> with any feedback about the listserv, with announcements/resources to share, or if you have any colleagues who would like to be added to the list. For more information about the resources shared, please reach out via the contact information on each item. Thank you!

In this email (click on header to jump to that item):

  *   Request for Abstracts: Joining Our Youth (JOY) Conference
  *   NASTAD RFP Release: Regional Centers of Excellence in Harm Reduction
  *   Clinical STI Update Webinar and New Doxy PEP for STI Prevention Clinician Guide
  *   SAMHSA and CDC Partner to Expand HIV and Viral Hepatitis Testing

________________________________
Request for Abstracts: Joining Our Youth (JOY) Conference

[JOY request for abstracts]The Oregon School-Based Health Alliance (OSBHA) is now accepting abstracts for their Joining Our Youth (JOY) Conference April 10-11, 2025 at Oregon State University in Corvallis.

The JOY Conference aims to build effective and genuine youth-adult partnerships, highlight the impact and innovation of school-based health centers, and identify how health/education systems can support young people and their families, particularly for communities who have been historically marginalized. The different tracks for this conference are youth engagement and empowerment, school health systems, policy and sustainability, clinical, and partnerships (more details and examples are in the Speaker Proposal Form).

If you are interested in submitting an abstract, please fill out the Speaker Proposal Form<https://links-2.govdelivery.com/CL0/https:%2F%2Fdocs.google.com%2Fforms%2Fd%2Fe%2F1FAIpQLSc7IR3ZxMO1BjOZ05C6jlAjlMgj6lDF8_RuYnAyk3OAk73tEQ%2Fviewform%3Futm_medium=email%26utm_source=govdelivery/1/010101939cebe346-e0781f77-dec4-4f79-bb54-5593528cb4b6-000000/NGyNk5-zOndgNOCeczlXWjDIc0lahCnkeRc4hnAkPLE=382>. The deadline to apply is January 17, 2025.

________________________________

NASTAD is releasing one of three requests for proposals as part of the CDC-supported Hub and Spoke Center of Excellence in Harm Reduction project.

Regional Centers of Excellence in Harm Reduction (Full RFP and application can be accessed here<https://nastad.org/careers/hub-and-spoke-centers-excellence-harm-reduction-regional-centers-excellence-harm-reduction>)
NASTAD is seeking applications from eligible organizations to become Regional Centers of Excellence (CoEs) in Harm Reduction. Regional CoEs will be funded and supported to provide local/regional harm reduction-related training, technical assistance, and capacity building activities and facilitate relationships among SSPs and between harm reduction programs and public health partners. This project aims to increase SSP sustainability and scale up best practices by building or expanding regional networks of mutual aid, collaboration, and cross-program learning.

Application Deadline: January 5, 2025, 11:59pm PST

Number of awards: 6 – 8

Award amounts may vary, anticipated funding is $85,000 - $125,000 per award

Period of performance: Year 1 of this program will run from February 1, 2025 - July 31, 2025

Please stay tuned for the other two RFPs related to this project, Key Projects and Subject Matter Expert Pool to support Regional Centers of Excellence, which will be released next week and can be found here<https://nastad.org/hub-and-spoke-centers-excellence-harm-reduction>.

Please contact DrugUserHealthTA at NASTAD.org<mailto:DrugUserHealthTA at NASTAD.org> with any questions. Thank you!

________________________________
Register Today!<https://uwptc.us17.list-manage.com/track/click?u=d8556173c86d02de69171c258&id=0e6284ec43&e=96876a4aea>

[https://mcusercontent.com/d8556173c86d02de69171c258/images/ab267ad4-cf00-aa44-18b0-0d17e968d13a.jpg]<https://uwptc.us17.list-manage.com/track/click?u=d8556173c86d02de69171c258&id=4663d6e758&e=96876a4aea>
Register Today!<https://uwptc.us17.list-manage.com/track/click?u=d8556173c86d02de69171c258&id=3b74aed1af&e=96876a4aea>

[https://mcusercontent.com/d8556173c86d02de69171c258/images/37de6565-d577-8feb-7793-4ddcbb142bfc.png]<https://uwptc.us17.list-manage.com/track/click?u=d8556173c86d02de69171c258&id=7770ff10ab&e=96876a4aea>

New Doxy PEP for STI Prevention Clinician Guide to Implement CDC June 2024 Guidelines
The NEW 16-page National STD Curriculum Clinician’s Information Guide: Doxy PEP for STI Prevention<https://uwptc.us17.list-manage.com/track/click?u=d8556173c86d02de69171c258&id=224e2b6b5c&e=96876a4aea> helps health care professionals implement CDC’s June 2024 guidelines<https://uwptc.us17.list-manage.com/track/click?u=d8556173c86d02de69171c258&id=0fa475d88d&e=96876a4aea> on the use of doxycycline postexposure prophylaxis (doxy PEP) for bacterial sexually transmitted infections. The guide addresses how and when to prescribe doxy PEP, what lab tests to order, and how to counsel patients. The guide also has an extensive FAQ and visual abstracts of the four key studies.
View this email in your browser<https://mailchi.mp/uw/uw-ptc-upcoming-january-sti-clinical-update-new-doxy-pep-for-sti-prevention-clinician-guide?e=96876a4aea>

UW Prevention Training Center Links & Useful Tools

Request PDF Visual Testing Guides<https://uwptc.us17.list-manage.com/track/click?u=d8556173c86d02de69171c258&id=a1329f2093&e=96876a4aea>
Request an STD Clinical Consult<https://uwptc.us17.list-manage.com/track/click?u=d8556173c86d02de69171c258&id=91352ad66d&e=96876a4aea>
National STD Curriculum<https://uwptc.us17.list-manage.com/track/click?u=d8556173c86d02de69171c258&id=1d15f7450a&e=96876a4aea>
Clinician’s Information Guide: Doxy PEP for STI Prevention<https://uwptc.us17.list-manage.com/track/click?u=d8556173c86d02de69171c258&id=c65e001d51&e=96876a4aea>
MPox Resources<https://uwptc.us17.list-manage.com/track/click?u=d8556173c86d02de69171c258&id=90c363515a&e=96876a4aea>

Register Today!<https://uwptc.us17.list-manage.com/track/click?u=d8556173c86d02de69171c258&id=1d7b85f4ab&e=96876a4aea>

Questions?
Please feel free to reach out with any questions or concerns.
uwptc at uw.edu<mailto:uwptc at uw.edu?subject=STD%20Update%3A%20Questions%2C%20Comments%2C%20Concerns>

________________________________

[https://res.subscribe.cdc.gov/res/cdc_mkt_prod1/e9e549b5260cd1651a2e5b5f04e9011a9706a0a0c1ff858634363b6c50dad140.png]

View Online<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc9011e&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=N5RHUiLXuAKJ1aivIERm2qPhze4q9BQU0FmOcMXY_m0>

December 9, 2024
Dear Colleagues,  

As the Assistant Secretary for Mental Health and Substance Use and leader of the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Director of the Centers for Disease Control and Prevention (CDC), we urge the public health and substance use disorder (SUD) treatment communities to increase the number of people with SUD who are tested and treated for HIV and viral hepatitis.

In the United States, an estimated 2.4 million people have hepatitis C, 1.2 million people have HIV, and 660,000 people have hepatitis B. Roughly 2 percent of those with HIV also have hepatitis B. Injection drug use is a risk factor for all three infections and is the most commonly reported risk factor for new hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. Further, one in four people with HIV who inject drugs also have hepatitis C. One in seven people with HIV, one in three people with HCV infection, and one in two people with HBV infection do not know they have it. According to the National Substance Use and Mental Health Services Survey, only a third of our nation’s 15,000 substance use disorder treatment facilities offer HIV, HCV, or HBV testing. This represents thousands of missed opportunities to ensure everyone knows their HIV, hepatitis C, and hepatitis B status and to link individuals to lifesaving treatment.

To increase the identification and treatment of all people with HIV and viral hepatitis, CDC recommends that all adults receive HIV, HBV, and HCV testing at least once in their lifetime. CDC also recommends:

  *   HIV testing<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc9011f&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=BrZBPh0bVnxu8mqvIwq0mqn0fSGEItGZQxreBuYW03U> at least once a year for people who share needles, syringes, or other drug injection equipment (for example, cookers) or exchange sex for drugs or money
  *   Routine periodic hepatitis C testing<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc90120&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=X8xF3kiB1xeEFj-z7JFMg_oeQTqbZ0wLfPJCwrUG3s0> for people with ongoing risk factors, including people who currently inject drugs and share needles, syringes, or other drug preparation equipment
  *   Routine periodic hepatitis B testing<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc90121&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=teYPoYBFqQ3OgFFGBlhfHYJrFjV9k6NJc4ASqNZIVMU> for people who inject drugs
  *   Clients without hepatitis B immunity, including adults age 19–59 and adults 60 and older with risk factors<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc90122&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=5m7g88vIgh5Lqu5hbhl2_QR7hoKGwAuyERqNxg9q9Hw>, should be vaccinated<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc90123&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=wlMtVfHSvY2v-cXcTe8KR_DIU_mB2OwuspeJiQWcUqw>
Testing is the first step to accessing lifesaving treatment. For example, hepatitis C treatment with oral direct-acting antivirals is curative in >95% of cases, prolongs life, is very well tolerated, and confers cost savings to the healthcare system by preventing HCV-related complications. Yet too few people are diagnosed, and only one-third of people with diagnosed hepatitis C have been treated or have naturally cleared the virus.xi At the end of June 2024, the FDA cleared a fingerstick point-of-care (POC) HCV RNA test<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc9044e&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=QTb-fvQqwt1miHvrCIm9y8QyJLiSFhxsCnUkrWi3DBU> for use in Clinical Laboratory Improvement Amendments (CLIA)-waived settings. This new POC test has the potential to revolutionize provider workflows and significantly reduce barriers to hepatitis C testing and treatment. Prior POC tests for the HCV antibody have only been able to diagnose previous exposure and not current infection, requiring multiple visits to test and connect people to treatment. Since the test takes 60 minutes or less to run, the new POC HCV RNA test can facilitate same-day diagnosis and rapid treatment initiation for hepatitis C. CDC recommends direct HCV RNA testing<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc9044f&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=AFUoyLCm2crsffPjMJ2BDbmYcoBr0gE6qkWGcWVeCJo> for people who might have been exposed to HCV within the past six months. Co-located hepatitis C treatment or highly accessible treatment through telehealth, mobile units, or warm handoffs to hepatitis C treatment providers is essential to actualize the benefit of POC HCV RNA testing. POC HCV RNA testing has the potential to significantly improve HCV testing and treatment rates in settings where people with SUD seek care.

People with SUD are at increased risk for HIV, and SUD treatment improves both HIV and SUD-related health outcomes. There are several FDA-approved POC tests for HIV<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc90450&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=lvXQdksrQned51c6EIYRIvPZnbLT9O_u3cJTgKyY_qw> that can be run on fingerstick whole blood or oral fluids in CLIA-waived settings. We reiterate an earlier appeal<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc90451&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=aQnbTPq5h83UfM5sQhda1jKn2FnowQ2lMhk0Dv2K-48> to increase POC HIV testing in SUD treatment programs. Linking people with HIV to treatment is essential to prolong their lives and prevent HIV transmission, and those who test negative may benefit further from being connected with HIV pre-exposure prophylaxis (PrEP)<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc90452&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=UkaDXtR0th6xB7ttPYbdK-T5dOhjzPwv6-29SnygJcg> and syringe service programs<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc90453&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=ckcqcYCgFjJcT-FiO3iMHaeVmNYfesVs5EywV8y0aqk>.

Integrating HIV and viral hepatitis testing in SUD treatment settings improves treatment initiation, especially when treatment is co-located, and is in line with SAMHSA’s 2023–2026 Strategic Plan<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc90454&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=7VQ5h1OEYyN4YiceJDAz9v1Tzkehqt6TPmWwoB1TAbo>, which prioritizes the integration of behavioral and physical healthcare. SAMHSA and CDC encourage SUD treatment facilities to integrate HIV and viral hepatitis testing, including POC HIV and HCV tests, into the services they offer their clients. Those who test positive should be connected to HIV or HCV treatment or offered on site when feasible. Information on integrating HIV<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc90455&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=8HTiSbKE58CTmMPHuCaGtfW0WcqszXufELpUzIomx14> and HCV<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc90456&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=FBIpS7baoLEPKmnJIwFs6DMp3gscQ8Xd3-nj2HW16ak> into SUD treatment is available. HCV POC testing may be an allowable expense for SAMHSA grant recipients—reach out to your SAMHSA Government Project Officer to assess feasibility; a budget revision may be necessary.

More than one million Americans are on medications for opioid use disorder, and millions more receive SUD treatment each year. It is our collective responsibility to ensure that they access screening and lifesaving treatment for HIV and viral hepatitis. Advancements in diagnostics are the first step to increasing testing, but we need your help to implement and use these new tools. Please consider integrating these POC diagnostics into your practice. With your help, we can increase HIV and viral hepatitis screening to ensure that no more families and communities have to lose loved ones to these preventable and treatable diseases.

Sincerely,

/Miriam Delphin-Rittmon/
Miriam E. Delphin-Rittmon, PhD
Assistant Secretary for Mental Health and Substance Use

/Mandy K. Cohen/
Mandy K. Cohen, MD, MPH
Director, Centers for Disease Control and Prevention

Note: This signed letter<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc90457&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=_2JieB5HcA84_jNYYcEkYhYO_Ywmo38ePPq0yUBRT30> is also available for downloading on CDC.gov<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc90458&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=G_pQsSR4wIGYFj0xM1NYoacZrLoxL4NhpFselQjEA64>.

References:

i Hall, Eric W et al. “Estimating hepatitis C prevalence in the United States, 2017-2020.” Hepatology (Baltimore, Md.), 10.1097/HEP.0000000000000927. 13 May. 2024, doi:10.1097/HEP.0000000000000927
ii "HIV Surveillance Supplemental Report: Estimated HIV Incidence and Prevalence in the United States, 2017– 2021,” 2023
iii Bixler D, Barker L, Lewis K, Peretz L, Teshale E. Prevalence and awareness of hepatitis B virus infection in the United States: January 2017–March 2020. Hepatol Commun 2023;7.
iv Bosh, K A et al. “HIV and viral hepatitis coinfection analysis using surveillance data from 15 US states and two cities.” Epidemiology and infection vol. 146,7 (2018): 920-930. doi:10.1017/S0950268818000766
v Ibid.
vi “HIV Surveillance Supplemental Report: Estimated HIV Incidence and Prevalence in the United States, 2017– 2021,” 2023
vii Lewis, Karon C et al. “Estimated Prevalence and Awareness of Hepatitis C Virus Infection Among US Adults: National Health and Nutrition Examination Survey, January 2017-March 2020.” Clinical infectious diseases: an official publication of the Infectious Diseases Society of America vol. 77,10 (2023): 1413-1415. doi:10.1093/cid/ciad411
viii Bixler D, Barker L, Lewis K, Peretz L, Teshale E. Prevalence and awareness of hepatitis B virus infection in the United States: January 2017–March 2020. Hepatol Commun 2023;7.
ix Substance Abuse and Mental Health Services Administration. (2023). National Substance Use and Mental Health Services Survey (N-SUMHSS) 2022: Annual Detailed Tables (SAMHSA Publication No. PEP23-07-00-002). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/.
x https://www.cdc.gov/hivnexus/hcp/diagnosis-testing/index.html; https://www.cdc.gov/hepatitis-b/hcp/diagnosis-testing/index.html; https://www.cdc.gov/hepatitis-c/hcp/diagnosis-testing/index.html
xi https://www.cdc.gov/mmwr/volumes/72/wr/mm7226a3.htm.

[CDC Facebook]<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc90459&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=gs3tXQV8xKV79MH_komxgZGFNHFgGxOuZ04Urp4Aai8>
[undefined]<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc9045a&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=tHioa_8cj3MLbTI8fQzXwW8F8h0VMsROY25zKIG0S8o>
[CDC Streaming Health]<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc9045b&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=0s86tjPSqhCVkD_MI7MxdiaN5YKRxTvCJ6TSulN3xug>
[CDC Instagram]<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc9045c&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=etB_IL1hQ5SHFEtjDCzScf4oiKq753VMs38FfqjbsEY>

Centers for Disease Control and Prevention
1600 Clifton Rd   Atlanta, GA 30329   1-800-CDC-INFO (800-232-4636)   TTY: 888-232-6348
Questions or Problems<https://t.emailupdates.cdc.gov/r/?id=h93faa65e,1dc25688,1dc9045d&e=QUNTVHJhY2tpbmdJRD1VU0NEQ05QSU5fMTYyLURNMTQyMDQzJkFDU1RyYWNraW5nTGFiZWw9U0FNSFNBJTIwYW5kJTIwQ0RDJTIwcGFydG5lciUyMHRvJTIwZXhwYW5kJTIwSElWJTIwYW5kJTIwdmlyYWwlMjBoZXBhdGl0aXMlMjB0ZXN0aW5n&s=5xBa0WaGK65aiOiEJeNkgdL77-gmUBWYIBgUE6Ks59k>

________________________________

Shelley Pearson
Pronouns: she/her/hers
HIV/STI Administrative and Communications Specialist
OREGON HEALTH AUTHORITY
Public Health Division
shelley.m.pearson at oha.oregon.gov<mailto:shelley.m.pearson at dhsoha.state.or.us>
Phone: 503-381-6173
Fax: 971-673-0178

[cid:image001.png at 01DB4BD6.F4214FF0]<http://www.endhivoregon.org/>

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <https://omls.oregon.gov/pipermail/hiv-std-prevention/attachments/20241211/559a2294/attachment-0001.html>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image001.png
Type: image/png
Size: 17451 bytes
Desc: image001.png
URL: <https://omls.oregon.gov/pipermail/hiv-std-prevention/attachments/20241211/559a2294/attachment-0001.png>